About JAMA Dermatology
Kanade Shinkai, MD, PhD
Editor
JAMA Dermatology is an international peer-reviewed journal that has been in continuous publication since 1882. It began publication by the ÁñÁ«ÊÓƵ in 1920 as Archives of Dermatology and Syphilology. The journal publishes material that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery. JAMA Dermatology is a member of the ÁñÁ«ÊÓƵ Network, a consortium of peer-reviewed, general medical and specialty publications.
Journal Frequency and Access. JAMA Dermatology is published online weekly, every Wednesday, and in 12 print/online issues a year. The journal receives more than 7.2 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's program.
Editorial Information. The journal's acceptance rate is 10%. The median time to first decision is 4 days, and 47 days with review. The Journal Impact Factor is 10.9, one of the highest ranking among dermatology journals. All articles are published online first. Additional information on the types of articles published and editorial policies is available in the journal's Instructions for Authors.
Editorial Team. Kanade Shinkai, MD, PhD, UCSF Department of Dermatology, San Francisco, California, is the editor in chief. For a complete listing of the journal's Editors and Editorial Board, see Editors and Publishers.
Mission Statement. JAMA Dermatology’s mission is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, to enable dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. The journal also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.
JAMA Dermatology
ISSN 2168-6068 (Print)
ISSN 2168-6084 (Online)
Back to top
Why Publish in JAMA Dermatology?
JAMA Dermatology publishes innovative, clinically relevant research that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery.
Impact and Reach
- Journal Impact Factor of 10.9, one of the highest ranking among dermatology journals
- Broad reach through related commentary, author audio interviews, podcasts, email alerts, multimedia, and more than 72,000 social media followers (Facebook, X, LinkedIn)
- More than 7.2 million annual article views and downloads
- International authors: 56% of submissions come from outside the United States
- Extensive press coverage, with over 5,600 media mentions in 2023 in outlets such as The New York Times, The Washington Post, The Wall Street Journal, and CNN
- Top Altmetric scores—JAMA Dermatology published 18 of the top 50 papers in the last year among dermatology journals
- Number of citations, Altmetric score, page views, and PDF downloads tracked for your published article
Prompt Decisions and Rapid Publication Timelines
- Highly selective peer review and editorial evaluation, with 10% acceptance rate for all submissions
- Median time to first decision: 4 days without external peer review; 47 days with review
- Expedited peer review and online publication for select clinical trials, other major studies, or reports with urgent public health importance
- Online First publication of all articles
- Coordination with meeting presentation: Opportunity to publish new research simultaneously with your presentation
Author Service
- User-friendly manuscript submission system and process
- Prompt, expert review and consideration from our experienced editors
- Highest standards followed to improve your accepted manuscript's accuracy, reliability, and readability
- CME credit available for lead authors who publish in JAMA Dermatology
- Opportunity for your work to be augmented with expert illustration, interactive features, video, audio, and visual abstract
- Display of content on fast, device-responsive website
- Citations, views, and Altmetric score displayed with every article
- Free public access: All research articles are freely available 12 months after publication on the journal's website
- Open access: Authors of research articles may elect to pay for immediate open access on the day of publication
- Deposit to PubMed Central: The journal deposits all published research articles into PubMed Central (PMC) for authors
- Authors may post accepted research manuscripts in public repositories on or after publication provided that they link to the published article on the journal website
- Online extras: Ability to post supplemental content online and download your article's tables and figures as PowerPoint slides
- The ÁñÁ«ÊÓƵ Network advantage: Authors of papers not accepted by JAMA Dermatology may have the option to have their papers and reviewers' comments automatically referred to one of the ÁñÁ«ÊÓƵ Network specialty journals and/or ÁñÁ«ÊÓƵ Network Open
- Dedicated media team to promote your article to the news media and on social media
Commitment to Equity
For more information, see JAMA Dermatology Instructions for Authors. Submit your manuscript at .
Back to top
Updated January 2024